References Santen and UBE received FDA approval for Omlonti ® (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure in patients with primary open ...

The Ocular Hypertension Treatment Study (OHTS) is a multicentered, randomized, controlled clinical trial with the primary goal to determine the safety and efficacy of topical ocular hypotensive ...

The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch activities for the implant are anticipated to begin in the first quarter of 2024.

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...

The safety and efficacy of iDose TR was based on 2 randomized, parallel-group, double-masked, controlled phase 3 trials (ClinicalTrials.gov Identifier: GC-010 [NCT03519386], GC–012 [NCT03868124 ...

Michael A. Kass, M.D., of Washington University School of Medicine, St. Louis, and colleagues in the Ocular Hypertension Treatment Study Group compared the safety and efficacy of earlier vs. later ...

The ocular hypertension treatment market is highly competitive, with major players including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, Noveome Biotherapeutics ...

Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20 ...

Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension Published Feb 19, 2025 8:02am EST ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera ...